Confo Therapeutics Funding: $106M Raised, Series B (2024)
Confo Therapeutics is based in Ghent, Belgium. It has raised $106M in total funding. Latest round: Series B.
Confo Therapeutics funding overview
Confo Therapeutics is based in Ghent, Belgium. Confo Therapeutics has raised $106M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in July 2024. The round record for Confo Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Ackermans & van Haaren, Driehaus Capital Management, Quest for Growth, BioGeneration Ventures, Capricorn Health-tech Fund, Fund+ and 7 others. 13 distinct backers are named across the disclosed rounds.
Confo Therapeutics at a glance
Total raised
$106M
Latest round
Series B
Latest round date
July 2024
Headquarters
Ghent, Belgium
Notable investors
Ackermans & van Haaren, Driehaus Capital Management, Quest for Growth, BioGeneration Ventures, Capricorn Health-tech Fund, Fund+, MINTS (University of Michigan), Perceptive Advisors
Frequently asked about Confo Therapeutics funding
How much has Confo Therapeutics raised?
Confo Therapeutics has raised $106M in total disclosed funding across the rounds on record.
Who has invested in Confo Therapeutics?
Ackermans & van Haaren, Driehaus Capital Management, Quest for Growth, BioGeneration Ventures, Capricorn Health-tech Fund, Fund+ are named among the investors backing Confo Therapeutics.
What was the latest Confo Therapeutics funding round?
The most recent disclosed round is a Series B, announced in July 2024.
Where is Confo Therapeutics based?
Confo Therapeutics is based in Ghent, Belgium.
When did Confo Therapeutics last raise?
The last disclosed Confo Therapeutics round closed in July 2024 at Series B.
Round data for Confo Therapeutics is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Ghent and backer lists below.
